Share CEConversations
Share to email
Share to Facebook
Share to X
By Creative Educational Concepts
4.9
3030 ratings
The podcast currently has 31 episodes available.
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial data for antibody-drug conjugates (ADCs); sequence optimization, combinatorial therapy utilization, and identification of when and in which patients to use ADCs; and anticipation, recognition, and management of treatment-related adverse events (TRAEs) in patients with metastatic urothelial cancer (mUC). Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.
Learn more: https://www.ceconcepts.com/activity/tailoring-patient-care-using-novel-agents-in-metastatic-urothelial-carcinoma-strategies-for-the-interprofessional-team/
Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT), primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact of CMV infection in patients with HSCTs or kidney transplants, the interdisciplinary care team managing these patients must have guidance on incorporating novel antiviral therapies into prevention and treatment schemas for CMV.
In this CME Outfitters recorded Grand Rounds series, expert faculty will emphasize the burden of CMV in kidney transplantation and HSCT, review the benefits and limitations of current antiviral agents, and discuss the role of novel antivirals (e.g., letermovir and maribavir) for managing CMV. Additionally, case studies will demonstrate how to integrate novel antivirals into clinical practice to improve quality of care and outcomes.
Learn more: | https://www.cmeoutfitters.com/activity/cytomegalovirus-in-stem-cell-and-kidney-transplant-overcoming-the-limitations-of-conventional-antiviral-therapy/
Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.
In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/
Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment options more acutely, leading to greater outcomes disparities. Antibody-drug conjugates (ADCs) are novel agents that may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether. This 90-minute enduring activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/transforming-metastatic-breast-cancer-management-harnessing-the-power-of-antibody-drug-conjugate-therapies-2/
Download the slides: https://www.ceconcepts.com/wp-content/uploads/2024/08/MM-140—ASCO—240606-1.pdf
Download the Transcript: https://www.ceconcepts.com/wp-content/uploads/2024/08/MMV-140-Transcript_FINAL.pdf
Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This information assists clinicians in creating treatment plans tailored to specific tumor phenotypes and individual needs, including those patients with advanced and recurrent EC. Despite ringing endorsements and clear clinical applications, however, molecular profiling remains underutilized due to logistical challenges and a lack of clinician confidence. It is imperative that clinicians, in collaboration with the multidisciplinary team (MDT), become knowledgeable about this exciting technique and utilize it to enhance treatment decisions for patients.
In this CE Concepts enduring webcast, expert faculty will guide learners through integration of appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process. Faculty will also assess the latest efficacy and safety data for the treatment of EC with learners and develop guideline-concordant and patient-specific therapeutic plans for patients with newly diagnosed advanced or recurrent EC that incorporate MDT collaboration strategies.
Learn More: | https://www.ceconcepts.com/activity/navigating-new-waters-for-advanced-or-recurrent-endometrial-cancer-2/
Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs). Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%). CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy. During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.
In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams. Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.
This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/
This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization as a means of providing foundational context for learners. Expert faculty will then lead attendees on an immersive, deep dive through the established paradigm and the preponderance of emerging data for novel weight-loss therapeutics, most notably the GLP-1 agonists and the GLP-1/GIP agonists. The session will conclude with a case-based segment, in which attendees will get to apply the principles they have learned to real-world clinical scenarios, address practical weight-loss challenges, and highlight the instrumental role of the primary care physician as a gatekeeper for the obesity management team. Request credit here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/
Supported through an independent educational grant from Lilly.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/igan-ee-podcast
This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.
Supported through an independent educational grant from Travere.
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.
Collect credit: https://www.ceconcepts.com/gu-cancer23-podcast
The podcast currently has 31 episodes available.